<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Advaxis, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Advaxis, Inc.

    Advaxis was founded on the vision that no one should suffer from the burdens of cancer. Our goal is to develop cancer immunotherapies that teach the body to recognize tumors as a threat and do so in a way that minimizes side effects associated with traditional chemotherapy and radiation. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Kenneth A. Berlin
    • FOUNDED
      2002
    • EMPLOYEES
      51-100
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    Organovo Holdings, Inc.

    Organovo Holdings, Inc.

    Organovo is a biotech platform company that has developed a leadership position wi...

    Organovo is a biotech platform company that has...

    Filing Type:    PU
    Delee Corp

    Delee Corp

    At Delee, we aim to radically change the way cancer is detected, monitored and tre...

    At Delee, we aim to radically change the way ca...

    Fundraising Status:    EC
    Filing Type:    CF
    SanMelix Laboratories, Inc.

    SanMelix Laboratories, Inc.

    Bringing faster healthier wound healing outcomes to trauma, burn victims and diabe...

    Bringing faster healthier wound healing outcome...

    Amount Raised:    $198,593.00
    Fundraising Status:    EC
    Filing Type:    CF
    NeoGenomics, Inc.

    NeoGenomics, Inc.

    NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and phar...

    NeoGenomics, Inc. is a high-complexity CLIA-cer...

    Filing Type:    PU
    Pacific Biosciences of California, Inc.

    Pacific Biosciences of California, Inc.

    Pacific Biosciences' mission is to transform the way humankind acquires, processes...

    Pacific Biosciences' mission is to transform th...

    Filing Type:    PU
    Zimmerman BioPharma Holding, Inc.

    Zimmerman BioPharma Holding, Inc.

    ZBP is a biopharmaceutical company that has developed a proprietary technology to ...

    ZBP is a biopharmaceutical company that has dev...

    Fundraising Status:    EC
    Filing Type:    RA
    AMAG Pharmaceuticals, Inc.

    AMAG Pharmaceuticals, Inc.

    Headquartered in Waltham, Massachusetts, we develop and deliver innovative medicin...

    Headquartered in Waltham, Massachusetts, we dev...

    Filing Type:    PU
    Neurocarrus Inc

    Neurocarrus Inc

    Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet ne...

    Neurocarrus is developing a breakthrough therap...

    Amount Raised:    $344,168.00
    Fundraising Status:    EC
    Filing Type:    CF
    Clovis Oncology, Inc.

    Clovis Oncology, Inc.

    Founded in 2009, Clovis Oncology (NASDAQ: CLVS) is a commercial stage biotechnolog...

    Founded in 2009, Clovis Oncology (NASDAQ: CLVS)...

    Filing Type:    PU
    Inovio Pharmaceuticals, Inc.

    Inovio Pharmaceuticals, Inc.

    Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of trea...

    Inovio is bringing IMMUNO-INGENUITY™ to life ...

    Filing Type:    PU
    Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals, Inc.

    Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...

    Spectrum Pharmaceuticals is a leading biotechno...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.